Integra LifeSciences (NASDAQ:IART) Releases Quarterly Earnings Results

Posted by Geri Gentry on Jul 29th, 2026

Integra LifeSciences (NASDAQ:IART – Get Free Report) announced its earnings results on Wednesday. The life sciences company reported $0.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.08, FiscalAI reports. The company had revenue of $418.76 million for the quarter, compared to analyst estimates of $417.54 million. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%. Integra LifeSciences updated its Q3 2026 guidance to 0.530-0.610 EPS and its FY 2026 guidance to 2.400-2.500 EPS.

Here are the key takeaways from Integra LifeSciences’ conference call:

Second-quarter execution improved: Revenue reached $419 million, up 0.7% organically, while adjusted EPS rose 24% year over year to $0.56 and exceeded the company’s guidance range. Gross margin expanded 60 basis points and adjusted EBITDA margin increased 160 basis points, supported by manufacturing efficiencies, lower remediation spending, and cost initiatives.
Integra reaffirmed its 2026 organic revenue growth outlook of 0.8%-3.3% and adjusted EPS guidance of $2.40-$2.50, but lowered reported revenue expectations to $1.654-$1.695 billion because of foreign-ex exchange impacts. Potentially higher second-half interest expense from a planned refinancing is expected to be offset by tariff benefits and additional cost savings.
Supply and product-relaunch milestones advanced: Manufacturing restarted at the Braintree facility, with inventory being built for a phased fourth-quarter SurgiMend relaunch. PriMatrix revenue has recovered to slightly above 50% of pre-recall levels, while DuraSorb continues to deliver double-digit growth.
The company expects longer-term growth from potential PMA approvals for SurgiMend and DuraSorb in implant-based breast reconstruction, with SurgiMend targeted for earlier 2027 and DuraSorb later in 2027, subject to FDA inspections and approval.
Tissue Reconstruction revenue declined 2% organically in the quarter, with Integra Skin facing a difficult comparison and MicroMatrix pressured by new competitors. ENT revenue also fell by low single digits as sinus-balloon reimbursement pressure outweighed growth in MicroFrance instruments.

Integra LifeSciences Stock Down 12.1%

Shares of Integra LifeSciences stock traded down $2.40 during trading on Wednesday, hitting $17.36. 1,036,713 shares of the stock traded hands, compared to its average volume of 897,065. The stock has a market cap of $1.35 billion, a P/E ratio of -2.69, a PEG ratio of 1.35 and a beta of 1.22. The company has a fifty day moving average price of $17.61 and a two-hundred day moving average price of $13.41. Integra LifeSciences has a twelve month low of $8.70 and a twelve month high of $20.49. The company has a debt-to-equity ratio of 1.75, a quick ratio of 1.95 and a current ratio of 3.38.

Wall Street Analyst Weigh In

IART has been the subject of several research analyst reports. BMO Capital Markets initiated coverage on shares of Integra LifeSciences in a research report on Wednesday, July 8th. They issued a “market perform” rating and a $19.00 price target for the company. Wells Fargo & Company raised their target price on Integra LifeSciences from $12.00 to $15.00 and gave the stock an “equal weight” rating in a research report on Wednesday, May 6th. Truist Financial lifted their price target on Integra LifeSciences from $14.00 to $19.00 and gave the company a “hold” rating in a report on Thursday, July 16th. Argus raised Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price target on the stock in a research report on Thursday, June 18th. Finally, Citigroup reissued a “neutral” rating and issued a $19.00 price objective (up from $16.00) on shares of Integra LifeSciences in a research note on Wednesday, July 8th. One research analyst has rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Reduce” and an average price target of $18.43.

Get Our Latest Report on Integra LifeSciences

Institutional Investors Weigh In On Integra LifeSciences

Institutional investors and hedge funds have recently modified their holdings of the business. Corient Private Wealth LLC acquired a new stake in shares of Integra LifeSciences in the fourth quarter worth about $189,000. Virtu Financial LLC bought a new stake in Integra LifeSciences during the fourth quarter worth approximately $124,000. Invesco Ltd. grew its holdings in Integra LifeSciences by 0.9% during the fourth quarter. Invesco Ltd. now owns 3,522,839 shares of the life sciences company’s stock valued at $43,754,000 after purchasing an additional 31,931 shares during the last quarter. State of Tennessee Department of Treasury raised its position in shares of Integra LifeSciences by 7.9% in the fourth quarter. State of Tennessee Department of Treasury now owns 26,745 shares of the life sciences company’s stock valued at $332,000 after purchasing an additional 1,964 shares during the period. Finally, Wellington Management Group LLP lifted its stake in shares of Integra LifeSciences by 2.4% in the fourth quarter. Wellington Management Group LLP now owns 1,353,467 shares of the life sciences company’s stock worth $16,810,000 after buying an additional 32,192 shares during the last quarter. Institutional investors and hedge funds own 84.78% of the company’s stock.

Integra LifeSciences News Summary

Here are the key news stories impacting Integra LifeSciences this week:

Positive Sentiment: Integra reported adjusted earnings of $0.56 per share, exceeding the $0.48 analyst consensus and increasing from $0.45 a year earlier. Revenue of $418.76 million was also slightly above the $417.54 million consensus. Integra LifeSciences Q2 Earnings Top Estimates
Positive Sentiment: Third-quarter guidance calls for EPS of $0.53-$0.61 and revenue of $410 million-$425 million, with the respective midpoints slightly above current analyst estimates of $0.56 per share and $417.3 million. Integra LifeSciences Reports Second Quarter 2026 Financial Results
Neutral Sentiment: Integra maintained a generally in-line full-year outlook, projecting 2026 EPS of $2.40-$2.50 versus the $2.45 consensus and revenue of approximately $1.7 billion. The guidance does not provide a clear upward revision to estimates. Integra Q2 Earnings Key Metrics Versus Estimates
Negative Sentiment: The company continues to report a negative net margin, which may temper enthusiasm despite the quarterly earnings beat. The market’s lower reaction indicates investors may have been looking for stronger full-year guidance or more evidence of sustained profitability. Integra LifeSciences Second Quarter 2026 Financial Results

About Integra LifeSciences

(Get Free Report)

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.